Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: SFW who wrote (2)	2/21/2000 2:17:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

Abed: >> Are there competing technologies to the one developed by NBSC? << As soon as I find out more detail to their approach, I'll try to answer. The patent may provide clues, or it may be completely unrelated to their current efforts. The tickler from the press release says "orally available"...... a proprietary process that offers pharmaceutical and biotechnology companies an improved method of identifying novel, small molecule, orally available drug leads. I see nothing in the patent that addresses this portion of the tickler. So, the next step is to check on European disclosures. If someone beats me to it, please post results.